Iron deficiency and safety of ferric carboxymaltose in patients with acute heart failure. AHF‐ID study

2020 ◽  
Vol 74 (10) ◽  
Author(s):  
Javier Jacob ◽  
Òscar Miró ◽  
Carles Ferre ◽  
Carmen Borraz‐Ordás ◽  
Guillermo Llopis‐García ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Acute Heart Failure ◽  
Ferric Carboxymaltose

scholarly journals Efficacy of intravenous ferric carboxymaltose for iron deficiency following acute heart failure (AHF) in patients with previously diagnosed HF: a subgroup analysis of AFFIRM-AHF

2021 ◽  
Vol 10 (Supplement_1) ◽  
Author(s):  
EA Jankowska ◽  
P Van Der Meer ◽  
M Metra ◽  
G Filippatos ◽  
BA Kirwan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Acute Heart Failure ◽  
Subgroup Analysis ◽  
Randomised Clinical Trial ◽  
Ferric Carboxymaltose ◽  
Private Company ◽  
Funding Sources ◽  
Death Time ◽  
History Of

Abstract Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Vifor Pharma OnBehalf The AFFIRM-AHF Investigators Introduction AFFIRM-AHF is the first randomised clinical trial to evaluate the effect of intravenous ferric carboxymaltose (IV FCM) (vs placebo) on morbidity and mortality in patients with an episode of acute heart failure (HF) and concomitant iron deficiency. Purpose To determine the effect of FCM versus placebo on efficacy outcomes in the subgroup of the AFFIRM-AHF cohort with a documented history of HF. Methods This subgroup analysis evaluated patients previously diagnosed with HF. Primary outcome was a composite of total HF hospitalisations and CV death. Secondary outcomes included total HF hospitalisations, CV death, time to first HF hospitalisation or CV death, composite of total CV hospitalisations and CV death, and days lost due to HF hospitalisations or CV death. All outcomes were evaluated up to 52 weeks post-randomisation. Results In AFFIRM-AHF, 73% and 70% of patients randomly assigned to FCM and placebo, respectively, had a documented history of HF. Baseline demographics and clinical characteristics were comparable between treatment groups for this subgroup. There were significantly fewer primary events in patients assigned to FCM compared to placebo: 249 vs 336, respectively (rate ratio [RR] 0.72, 95% CI: 0.55–0.95; p = 0.022). 186 total HF hospitalisations occurred in FCM group and 267 in placebo (RR 0.67, 95% CI: 0.52–0.88; p = 0.004). The composite of first HF hospitalisation or CV death occurred in 149 (37%) assigned FCM and in 179 (44%) patients assigned placebo (hazard ratio [HR] 0·76, 95% CI: 0·61–0·95; p = 0·014). Conclusion   In patients with a documented history of HF and iron deficiency who were stabilised after an episode of AHF, treatment with FCM significantly reduced the risk of a composite of total HF hospitalisation and CV death. Primary and Secondary outcomesFCM (n = 405)Placebo (n = 385)RR or HR (95% CI)P valueNo. of eventsRate per 100 patient-yrNo. of eventsRate per 100 patient-yrPrimary outcomeTotal HF hospitalisations and CV death24971.85336101.3RR: 0.72 (0.55-0.95)0.022Secondary outcomesTotal CV hospitalisationsand CV death30888.87401120.57RR: 0.74 (0.58-0.95)0.020Time to CV death63346.5568332.58HR: 0.91 (0.65-1.29)0.602Total HF hospitalisations18653.6726780.28RR: 0.67 (0.52-0.88)0.004Time to first HF hospitalisation or CV death149291.76179257.93HR: 0.76 (0.61-0.95)0.014Days lost due to HF hospitalisation and CV death4.5*526.328.3*955.55RR: 0.58 (0.38-0.90)0.015*Data point is the mean number of days lost per subject.

scholarly journals Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

The Lancet ◽  
2020 ◽  
Vol 396 (10266) ◽  
pp. 1895-1904 ◽  
Author(s):  
Piotr Ponikowski ◽  
Bridget-Anne Kirwan ◽  
Stefan D Anker ◽  
Theresa McDonagh ◽  
Maria Dorobantu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Randomised Controlled Trial ◽  
Iron Deficiency ◽  
Acute Heart Failure ◽  
Controlled Trial ◽  
Ferric Carboxymaltose ◽  
Double Blind ◽  
Randomised Controlled

scholarly journals Expert consensus regarding treatment of iron deficiency in stable and decompensated patients with heart failure

Kardiologiia ◽  
2021 ◽  
Vol 61 (4) ◽  
pp. 73-78
Author(s):  
Yu. V. Mareev ◽  
S. R. Gilarevsky ◽  
Yu. L. Begrambekova ◽  
Yu. M. Lopatin ◽  
A. A. Garganeeva ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ferric Carboxymaltose ◽  
Ventricular Ejection Fraction ◽  
Patients With Heart Failure ◽  
High Prevalence ◽  
Acute Decompensation

In recent years there has been significant interest in treating iron deficiency (ID) in patients with heart failure (HF) due to its high prevalence and detrimental effects in this population. As stated in the 2020 Russain HF guidelines, Intravenous ferric carboxymaltose remains the only proven therapy for ID.This document was prompted by the results from the recent AFFIRM-AHF trial which demonstrates that treatment of ID after acute HF decompensation reduces the risk of future decompensations. Experts have concluded that in HF patients with acute decompensation, a left ventricular ejection fraction of < 50% and ID, Intravenous ferric carboxymaltose reduces future HF hospitalisations. Patients with stable HF may also benefit from treatment of ID to improve quality of life and alleviate symptoms.  It is, therefore, reasonable to screen for and treat ID in patients with HF.

scholarly journals Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

2009 ◽  
Vol 361 (25) ◽  
pp. 2436-2448 ◽  
Author(s):  
Stefan D. Anker ◽  
Josep Comin Colet ◽  
Gerasimos Filippatos ◽  
Ronnie Willenheimer ◽  
Kenneth Dickstein ◽  
...  
Keyword(s):  
Heart Failure ◽  
Iron Deficiency ◽  
Ferric Carboxymaltose ◽  
Patients With Heart Failure
Sign in / Sign up

Export Citation Format

Share Document